cst falling of the cliff, page-38

Hi Forest - thanks for your valuable input to this forum over many years.
I recently learned that a relative is involved in TB research working in South America. I asked his Dad to ask him if he'd heard of CST and QF - this was the reply I received -

"I spoke to R - he knows the company, and has just arranged an attractive price from them for tests in connection with his research. Careful, though - R has a mate who is developing an alternative test (at 1.50 per shot instead of Cellestis's 10) which also shows drug-resistance, while Cellestis only shows infection. I don't know how far this is from commercial use. but I have known vaguely about it for a couple of years."

Just wondering if there's an awareness in the market of a competitor product that's effecting the CST share price. Maybe there's some expectation of an imminent announcement by a competitor?
Can you make any sense of the comment about the alternative test mentioned also indicating drug-resistance while QF only indicates infection?

Anyway it was good to get confirmation from someone on the ground that CST is out there, active and working at building a presence.

Best wishes to all for the new decade